$CLVT

CLARIVATE PLC (CLVT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. clvt-20260724 0001764046 false 00-0000000 0001764046 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event

Original reporting
Published Jul 29, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CLVT
Neutral
medium confidence
Mentioned
$CLVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLVTNeutralLow
01

Why it matters

CFO and Chief Accounting Officer transitions can affect investor confidence in financial reporting quality and capital allocation discipline, but this filing provides no new financial metrics or guidance.

02

Market read

Traders may adjust short-term sentiment and governance risk assumptions for CLVT ahead of the effective-date transition, but there is no direct earnings or guidance catalyst.

03

What to watch

Watch for subsequent 10-Q/8-K exhibits (full offer letter) and any later disclosures about internal controls, reporting changes, or auditor communications that could change the risk profile.

Relevance 6/10Novelty 5/10Timing: effective Aug. 7 to Aug. 8, 2026 CFO and Chief Accounting Officer transition

Background

The 8-K (Item 5.02) reports executive departures and appointments, including CFO and Chief Accounting Officer changes, plus revised offer letter compensation details.

Company-level read

Ticker impact

$CLVTNeutralMedium confidence
Context

Clarivate disclosed CFO Jonathan Collins’ resignation effective Aug. 7, 2026 and appointed Michael Easton as CFO effective Aug. 8, 2026.

Expected impact

Low near-term impact; any move is more likely sentiment-driven around execution continuity than a direct financial re-rating.

Evidence & confidence

The filing is a primary-source 8-K for executive appointments, but it does not include guidance, financial results, restatements, or material transactions beyond compensation and role changes.

Market effects

Limited sector read-through; this is company-specific finance leadership continuity rather than an industry-wide regulatory or accounting change.

Primarily affects US-listed Clarivate (NYSE: CLVT) sentiment; no stated regional operational impact.

No global macro or cross-border transaction disclosed; impact is confined to Clarivate’s corporate governance and finance function.

Counterpoint

The CFO change could still signal internal issues not described in the 8-K, so traders may over-discount the risk of future accounting or control problems.

Key entities

  • Clarivate Plc

    Company filing the 8-K; disclosed CFO and Chief Accounting Officer changes and compensation terms.

  • Jonathan Collins

    Executive Vice President and Chief Financial Officer who resigned effective Aug. 7, 2026.

  • Michael Easton

    Appointed Executive Vice President and Chief Financial Officer effective Aug. 8, 2026; previously Senior Vice President, Finance and Chief Accounting Officer.

  • Matthew Lisowski

    Appointed Senior Vice President, Chief Accounting Officer effective Aug. 8, 2026.

Related articles

$CLVTMed

Clarivate Plc Q2 2026 Earnings Call Summary

Clarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.

$CLVTMed

Clarivate Reports Second Quarter 2026 Results

Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.

$CLVTMedAI 8/10

CLARIVATE PLC (CLVT): Results of Operations and Financial Condition

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026earningsrelease.htm EX-99.1 Ex. 99.1 Q2 2026 Earnings Release 1 Clarivate Reports Second Quarter 2026 Results — Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile wit

$CLVTMedAI 8/10

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate (NYSE:CLVT) will sell its Life Sciences & Healthcare unit to Altaris for $600M to refocus on Academia & Government and Intellectual Property, according to company executives. Clarivate affirmed 2026 guidance midpoints except free cash flow, citing added transaction costs. Pro forma revenue and adjusted EBITDA would be down about $370M and $120M, but free cash flow is expected to hold.